نتائج البحث

المصدر: Hendriks , L E , Kerr , K M , Menis , J , Mok , T S , Nestle , U , Passaro , A , Peters , S , Planchard , D , Smit , E F , Solomon , B J , Veronesi , G , Reck , M , ESMO Guidelines Committee & Guidelines Committee , ESMO 2023 , ' Oncogene-addicted metastatic non-small-cell lung cancer : ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ' , Annals of Oncology , vol. 34 , no. 4 , pp. 339-357 . https://doi.org/10.1016/j.annonc.2022.12.009Test

مصطلحات موضوعية: ESCAT, ESMO Clinical Practice Guideline (CPG), ESMO-MCBS, oncogene-addicted metastatic non-small-cell lung cancer (mNSCLC), treatment, targeted therapy, TYROSINE KINASE INHIBITORS, PROGRESSION-FREE SURVIVAL, RESPONSE EVALUATION CRITERIA, FACTOR RECEPTOR MUTATIONS, OPEN-LABEL, 1ST-LINE TREATMENT, SINGLE-ARM, TREATMENT-NAIVE, EGFR MUTATIONS, ADVANCED NSCLC

وصف الملف: application/pdf

العلاقة: https://cris.maastrichtuniversity.nl/en/publications/a6c20759-e209-411f-b9b7-789fc32e2f64Test

الإتاحة: https://doi.org/10.1016/j.annonc.2022.12.009Test
https://cris.maastrichtuniversity.nl/en/publications/a6c20759-e209-411f-b9b7-789fc32e2f64Test
https://cris.maastrichtuniversity.nl/ws/files/192165782/Hendriks-2023-Oncogene-addicted-metastatic-non-small.pdfTest

View record in BASE

4

دورية أكاديمية

Lipid nanoparticle delivery alters the adjuvanticity of the TLR9 agonist CpG by innate immune activation in lymphoid tissue

المؤلفون: Zhong, Zifu, Chen, Yong, Deswarte, Kim, Lauwers, Heleen, De Lombaerde, Emily, Cui, Xiaole, Van Herck, Simon, Ye, Tingting, Gontsarik, Mark, Lienenklaus, Stefan, Sanders, Niek, Lambrecht, Bart, De Koker, Stefaan, De Geest, Bruno

المصدر: ADVANCED HEALTHCARE MATERIALS ; ISSN: 2192-2640 ; ISSN: 2192-2659

مصطلحات موضوعية: Medicine and Health Sciences, Pharmaceutical Science, Biomedical Engineering, Biomaterials, CpG ODN, immune therapy, lipid nanoparticles, TLR9, vaccine adjuvants, 1ST-LINE TREATMENT, RECOGNITION, RECEPTORS, CELLS, MODEL, DNA

وصف الملف: application/pdf

العلاقة: https://biblio.ugent.be/publication/01HMB3J8RDAHVDEFAY7FHH7HA6Test; http://hdl.handle.net/1854/LU-01HMB3J8RDAHVDEFAY7FHH7HA6Test; http://doi.org/10.1002/adhm.202301687Test; https://biblio.ugent.be/publication/01HMB3J8RDAHVDEFAY7FHH7HA6/file/01HMB430E3T4FVFB6991RGQCYETest

الإتاحة: https://doi.org/10.1002/adhm.202301687Test
https://biblio.ugent.be/publication/01HMB3J8RDAHVDEFAY7FHH7HA6Test
http://hdl.handle.net/1854/LU-01HMB3J8RDAHVDEFAY7FHH7HA6Test
https://biblio.ugent.be/publication/01HMB3J8RDAHVDEFAY7FHH7HA6/file/01HMB430E3T4FVFB6991RGQCYETest

View record in BASE

5

دورية أكاديمية

Development and validation of a decision model for the evaluation of novel lung cancer treatments in the Netherlands

المؤلفون: Mfumbilwa, Zakile A, Wilschut, Janneke A, Simons, Martijn J H G, Ramaekers, Bram, Joore, Manuela, Retèl, Valesca, der Welle, Christine M Cramer-van, Schramel, Franz M N H, van de Garde, Ewoudt M W, Coupé, Veerle M H

المساهمون: Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP – Centre for Clinical Therapeutics

مصطلحات موضوعية: Humans, Antineoplastic Agents/adverse effects, Netherlands, Cost-Benefit Analysis, Lung Neoplasms/drug therapy, Carcinoma, Non-Small-Cell Lung/drug therapy, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Competing risks, Multicenter, Tyrosine kinase inhibitors, Survival outcomes, Cost-effectiveness analysis, Chemotherapy, Pembrolizumab, Simulation, Immunotherapy, 1st-line therapy, General

وصف الملف: application/pdf

العلاقة: https://dspace.library.uu.nl/handle/1874/427599Test

الإتاحة: https://dspace.library.uu.nl/handle/1874/427599Test

View record in BASE

النص الكامل

6

دورية أكاديمية

Amivantamab plus lazertinib in osimertinib-relapsed EGFR -mutant advanced non-small cell lung cancer: a phase 1 trial

المساهمون: Kim, Dong-Wan

مصطلحات موضوعية: TYROSINE KINASE INHIBITORS, ANTIBODY TARGETING EGFR, BISPECIFIC ANTIBODY, OPEN-LABEL, PROTEIN EXPRESSION, 1ST-LINE TREATMENT, CHEMOTHERAPY, RESISTANCE, NSCLC, MULTICENTER

العلاقة: Nature Medicine, Vol.29 No.10, pp.2577-2585; https://hdl.handle.net/10371/195815Test; 001068088400002; 2-s2.0-85171288172; 195096

الإتاحة: https://doi.org/10.1038/s41591-023-02554-7Test
https://hdl.handle.net/10371/195815Test

View record in BASE

7

دورية أكاديمية

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer

المساهمون: Im, S.-A.

مصطلحات موضوعية: ALPELISIB PLUS FULVESTRANT, PHASE-III TRIAL, DOUBLE-BLIND, SACITUZUMAB GOVITECAN, OPEN-LABEL, 1ST-LINE THERAPY, TRASTUZUMAB DERUXTECAN, REPORTED OUTCOMES, BRAIN METASTASIS, FINAL ANALYSIS, ESMO, guidelines, metastatic breast cancer, Pan-Asian, treatment

العلاقة: Esmo Open, Vol.8 No.3, p. 101541; https://hdl.handle.net/10371/194677Test; 001044740800001; 2-s2.0-85159041839; 185406

الإتاحة: https://doi.org/10.1016/j.esmoop.2023.101541Test
https://hdl.handle.net/10371/194677Test

View record in BASE

النص الكامل

8

دورية أكاديمية

Real-world outcomes upon second-line treatment in patients with chronic lymphocytic leukaemia

المؤلفون: Vainer, Noomi, Aarup, Kathrine, Andersen, Michael Asger, Wind-Hansen, Lise, Nielsen, Tine, Frederiksen, Henrik, Enggaard, Lisbeth, Poulsen, Christian Bjorn, Niemann, Carsten U., Rotbain, Emelie C.

المصدر: Vainer , N , Aarup , K , Andersen , M A , Wind-Hansen , L , Nielsen , T , Frederiksen , H , Enggaard , L , Poulsen , C B , Niemann , C U & Rotbain , E C 2023 , ' Real-world outcomes upon second-line treatment in patients with chronic lymphocytic leukaemia ' , British Journal of Haematology , vol. 201 , no. 5 , pp. 874-886 . https://doi.org/10.1111/bjh.18715Test

مصطلحات موضوعية: adverse events, chronic lymphocytic leukaemia, survival, targeted treatment, treatment effect, OPEN-LABEL, CLL-IPI, IBRUTINIB, VENETOCLAX, RITUXIMAB, THERAPY, METAANALYSIS, 1ST-LINE, PHASE-2, OLDER